Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing

Aktis Oncology, Inc.

2026-Q1 EPS reported -$0.38 revenue$3,227,000

Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.
Cash, equivalents & marketable securities $538.5M (up from $226.8M Dec 2025); runway into 2029.
Initiated Phase 1b trial of AKY-2519 in mCRPC; second basket trial in H2 2026 for solid tumors.
AKY-1189 Phase 1b enrolling in multiple Nectin-4 tumors; preliminary data expected Q1 2027; FDA Fast Track for urothelial cancer.
Collaboration revenue $3.2M from Eli Lilly; appointed Glenn Gormley, MD, PhD to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.